Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
NovoLog (insulin aspart) and Ozempic (semaglutide) are both medications used to manage diabetes, but they belong to different drug classes and have distinct uses. NovoLog is a fast-acting insulin used to treat both Type 1 and Type 2 diabetes by helping your body absorb sugar from the bloodstream. It is typically injected one or more times a day before meals. On the other hand, Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist used for Type 2 diabetes and to lower the risk of heart problems in adults with Type 2 diabetes and heart disease. It is injected once a week. NovoLog is available in vials and prefilled pens, while Ozempic comes as a prefilled pen. Common side effects of NovoLog include low blood sugar and headaches, whereas Ozempic may cause nausea, vomiting, and diarrhea. NovoLog can lead to weight gain, while Ozempic might cause weight loss. Both medications require careful monitoring of blood sugar levels, and they have different storage requirements and dosing schedules.
Novolog (insulin aspart)
Ozempic (semaglutide)
Novolog (insulin aspart)
Ozempic (semaglutide)
Summary of Novolog vs. Ozempic
Summary for Insulin
Prescription only
NovoLog (insulin aspart) is a fast-acting insulin for adults and children with diabetes. It lowers your blood sugar levels by moving the sugar into your body so it can be used for energy. NovoLog (insulin aspart) is available as vials and ready-to-use prefilled pens. It's typically injected under the skin at mealtimes, but it can also be given as an infusion into the veins by a healthcare provider for people in the hospital. Side effects include headache and low blood sugar (hypoglycemia).
Summary for GLP-1 agonist
Prescription only
Ozempic (semaglutide) is a prescription injection used with diet and exercise to help manage Type 2 diabetes in adults. It's also FDA approved to lower the risk of heart attack, stroke, and heart-related death in those with Type 2 diabetes and heart disease. In addition, it can reduce the risk of worsening kidney problems in people with Type 2 diabetes and chronic kidney disease (CKD). Ozempic (semaglutide) is a GLP-1 agonist that's injected under the skin once a week. Common side effects include nausea, vomiting, and diarrhea.